Drug Discovery Informatics Market Size Worth USD 8,132.56 Million by 2032 | CAGR: 10.9%

The global drug discovery informatics market size is expected to reach USD 8,132.56 million by 2032, according to a new study by Polaris Market Research. The report “Global Drug Discovery Informatics Market Size, Share, Trends, Industry Analysis Report: Information By Application (Drug Discovery, Drug Development), By Mode, By Services, By End-User, and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Technological advancements such as integration with artificial intelligence and cloud computing are propelling the growth of the drug discovery informatics market. Several technology-based companies are introducing drug discovery solutions to meet the burgeoning needs of the healthcare industry. The application of AI in healthcare is revolutionizing the drug discovery process, making it more adept at handling the complexity of biomedical data. Therefore, innovative technological upgrades are propelling the growth of the drug discovery informatics market.

Moreover, the substantial investments made by companies to accelerate drug discovery processes are also fueling market growth. These investments have bolstered the capabilities of drug discovery informatics, paving the way for innovative therapeutics. Consequently, the combination of advanced informatics models with substantial financial backing is fostering drug development, thus stimulating the growth of the drug discovery informatics market.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/drug-discovery-informatics-market/request-for-sample

The expansion and growth activities of industry players also fuel the development of drug discovery informatics. The activities include acquisitions, collaborations, and partnerships with research organizations, academic institutions, and pharmaceutical companies to drive innovation in the market. Moreover, the drug discovery informatics market is competitive, with several global and regional players vying for market dominance. Global players are dominating the market with innovative offerings that cover AI-driven insights, data analytics, and cloud-based solutions tailored specifically for pharmaceutical research.

Drug Discovery Informatics Market Report Highlights

• The market's drug development segment is expected to experience substantial growth in the coming years due to the rising research and development activities by pharmaceutical companies.
• In 2023, the sequence analysis platforms segment dominated the market in terms of revenue because advanced platforms such as BLAST, FASTA, and CLUSTALW significantly facilitated modern drug discovery and development. These platforms empowered researchers to analyze and interpret vast amounts of genomic data efficiently.
• The North American drug discovery informatics market held the largest revenue share due to the presence of a robust pharmaceutical industry.
• The growing interest of global drug discovery informatics companies in China as a key player in drug discovery and development is expected to drive the growth in the China drug discovery informatics market.
• The global key market players are Accenture, Agilent Technologies, Inc., Boehringer Ingelheim International GmbH, Certara, Charles River Laboratories, Chemaxon Ltd., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products, Illumina, Inc., Infosys Limited, Jubilant Biosys Ltd., Oracle, QIAGEN, Sapio Sciences, and Selvita.

Polaris Market Research has segmented the drug discovery informatics market report based on application, mode, services, end-user, and region:

Drug Discovery Informatics, Application Outlook (Revenue - USD Million, 2019 - 2032)

• Drug Discovery

• Identification, Validation, & Assay Development Informatics
• Lead Generation

• Drug Development

• FHD Preparation
• Lead Optimization
• Phase IA
• Phase IB/2

Drug Discovery Informatics, Mode Outlook (Revenue - USD Million, 2019 - 2032)

• Outsourced
• In-house

Drug Discovery Informatics, Services Outlook (Revenue - USD Million, 2019 - 2032)

• Clinical Trial Data Management
• Docking
• Molecular Modeling
• Sequence Analysis Platforms
• Others

Drug Discovery Informatics, End User Outlook (Revenue - USD Million, 2019 - 2032)

• Biotechnology Companies
• Contract Research Organization (CROs)
• Pharmaceutical Companies
• Others

Drug Discovery Informatics, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of APAC

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of MEA

Drug Discovery Informatics Report Scope